Anifrolumab PK Study for Systemic Lupus Erythematosus (SLE)
NCT05001698 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15
Last updated 2022-08-18
Summary
To assess the pharmacokinetic parameters of anifrolumab in Chinese participants with active systemic lupus erythematosus(SLE).
Conditions
Interventions
- BIOLOGICAL
-
Anifrolumab
intravenous infusion (IV)
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-07-27
- Primary Completion
- 2022-06-02
- Completion
- 2022-06-02
Countries
- China
Study Locations
More Related Trials
-
Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus
NCT00556192 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
NCT05138133 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
NK510 Cell Therapy for Refractory Systemic Lupus Erythematosus
NCT07083349 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
CNCT19 Cell Injection for Refractory Systemic Lupus Erythematosus
NCT05930314 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE)
NCT04908865 ·Status: COMPLETED ·Phase: PHASE4
-
Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases
NCT06411639 ·Status: WITHDRAWN ·Phase: PHASE1
-
Safety and Efficacy Study of CC312 for Moderate to Severe SLE
NCT07177911 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)
NCT04305197 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus
NCT02880852 ·Status: COMPLETED ·Phase: PHASE1
-
Anifrolumab Malignancy and Serious Infections Study
NCT07000110 ·Status: RECRUITING
-
Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.
NCT03610516 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus
NCT04582136 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE)
NCT07266090 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of SHR-2173 in Patients With Systemic Lupus Erythematosus
NCT06955598 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations
NCT02962960 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
NCT06916806 ·Status: RECRUITING ·Phase: PHASE1
-
JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus
NCT05967520 ·Status: RECRUITING ·Phase: PHASE2
-
Single Dose Study to Investigate the Pharmacokinetics (PK) and Safety of Belimumab 200 Milligrams (mg) Intravenous and 200 mg Subcutaneous Via Auto-injector in Chinese Healthy Subjects
NCT04136145 ·Status: COMPLETED ·Phase: PHASE1
-
Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus
NCT07010835 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus.
NCT01559090 ·Status: COMPLETED ·Phase: PHASE2
-
An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus
NCT05798117 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Leflunomide in Systemic Lupus Erythematosus
NCT00637819 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
NCT02446912 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
NCT02446899 ·Status: COMPLETED ·Phase: PHASE3
-
Long-Term Outcomes in SLE at Peking University People's Hospital
NCT07005479 ·Status: RECRUITING